These findings suggest that glycosylated delphinidines have potential as adjuvants in the treatment of glioblastoma, and their role in regulating NF-κB and MGMT activity opens new avenues for the development of targeted therapies (Figure 7). This evidence concerns the gene NFKB1 and glioblastoma.